Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Celebrates Indian Independence Day by Honoring the US-India Innovation Partnership

CAMBRIDGE, Mass.–(BUSINESS WIRE)–$HIND–Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, will be ringing the Nasdaq Opening Bell today in honor of its first day of trading as “HIND.” The occasion will also mark India’s 79^th Independence Day.

“The HIND journey begins today, a journey in which anyone, anywhere in the world can now participate thanks to our stock being on Nasdaq,” said Krishna Gupta, Chairman of Vyome. “Our commitment to shareholders is simple: every decision we make will be in their best interests because we have no debt and because our board is smart and heavily aligned with shareholders.”

“Our innovation pipeline is very deep and we have access to world-class talent in both the US and India,” said Shiladitya Sengupta, Founder of Vyome and Associate Professor of Medicine at Harvard Medical School. “Our immediate focus will be to unlock the value of our clinical stage assets that all revolve around major unmet needs in the $100 billion immuno-inflammatory market, but our vision extends well beyond that.”

“This milestone is the result of phenomenal teamwork across continents – from our scientists and clinicians to our partners and advisors and most importantly our key investors – all united by a shared vision. We are committed to cost-effective operations to create maximal value for all our shareholders going forward,” said Venkat Nelabhotla, Co-founder and CEO of Vyome.

“It is such an honor to celebrate India’s Independence Day at the Nasdaq, which we believe is a first,” added Gupta. “We believe in the special relationship between the US and India, we are a product of it, and we are confident it will be the defining partnership of the next decade – whether in Healthcare, AI, or a number of other innovation-related corridors. Jai HIND and God Bless AMERICA!”

Maxim Group LLC served as financial advisor to ReShape in connection with the transactions and Fox Rothschild LLP acted as its legal counsel. Chardan served as financial advisor to Vyome for the merger and Sichenzia Ross Ference Carmel LLP acted as its legal counsel.

About Vyome

Vyome is building a healthcare platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome’s immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit www.vyometx.com

Visit us on social media:

Facebook
X
LinkedIn

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project,” “outlook”, and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Examples of forward-looking statements include, among others, statements made in this release regarding the merger, including the benefits of the merger, revenue opportunities, anticipated future financial and operating performance, and results, including estimates for growth. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vyome’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (a) the occurrence of any event, change, or other circumstances relating to the combined company; (b) failure to obtain the necessary consents and approvals; (c) the risk that the merger disrupts current plans and operations as a result of the announcement and consummation of the merger; (e) costs related to the merger; and (f) changes in applicable laws or regulations. Vyome cautions that the foregoing list of factors is not exhaustive. Vyome cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Vyome does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, whether as a result of new information, future events, or otherwise, except as may be required by applicable law.

Contacts

Media contact:

ICR for Vyome

VyomePR@icrinc.com